HSBC Holdings
PRLD icon

HSBC Holdings’s Prelude Therapeutics PRLD Stock Holding History

HSBC Holdings’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.4K Hold
13,652
– – ﹤0.01% 2832
2026
Q1 		$47.9K Hold
13,652
– – ﹤0.01% 2809
2025
Q4 		$39.5K Sell
13,652
-95
-0.7% -$160 ﹤0.01% 2876
2025
Q3 		$20.2K Sell
13,747
-3,664
-21% -$3.67K ﹤0.01% 2673
2025
Q2 		$13.9K Sell
17,411
-3,219
-16% -$2.79K ﹤0.01% 2990
2025
Q1 		$17.5K Sell
20,630
-10
-0% -$9 ﹤0.01% 2973
2024
Q4 		$25.6K Sell
20,640
-132
-0.6% -$175 ﹤0.01% 3044
2024
Q3 		$43.8K Sell
20,772
-4,133
-17% -$19.1K ﹤0.01% 2891
2024
Q2 		$90.7K Hold
24,905
– – ﹤0.01% 2747
2024
Q1 		$118K Buy
24,905
+1,695
+7% +$6.59K ﹤0.01% 2814
2023
Q4 		$93.8K Buy
23,210
+12
+0.1% +$37 ﹤0.01% 2605
2023
Q3 		$70.8K Buy
+23,198
New +$87K ﹤0.01% 2595

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

HSBC Holdings's PRLD Position: Q2 2026 in Review

HSBC Holdings held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 13,652 shares worth $74.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2832.

HSBC Holdings first reported a position in PRLD in Q3 2023 and has held it in 12 quarters since. The position peaked at $118K in Q1 2024. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • HSBC Holdings held 13,652 shares of Prelude Therapeutics worth $74.4K as of Q2 2026.
  • HSBC Holdings left its Prelude Therapeutics share count unchanged in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2832 holding.
  • HSBC Holdings first reported a position in Prelude Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • HSBC Holdings's Prelude Therapeutics position peaked at $118K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.